JPND
The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has announced an €18 million transnational call for multinational research on novel imaging and brain stimulation methods and technologies for neurodegenerative diseases.
With neurodegenerative diseases on the rise and strongly linked to age, as many as 47 million people worldwide are estimated to be suffering from Alzheimer’s and related disorders today. This figure is expected to double every 20 years as the population ages. JPND was established in order to better coordinate research efforts across countries and disciplines to find causes more rapidly, develop cures and identify better ways to care for people with neurodegenerative diseases.
In recent years, major increases in the range and power of technologies across the basic, clinical and patient-centered domains of JPND have been seen. These include the use of imaging and analysis technologies, from Magnetic Resonance Imaging (MRI) to Position Emission Tomography (PET) to Molecular Imaging at both a molecular and a whole body imaging level, and the use of brain stimulation techniques such as Deep Brain Stimulation (DBS), Neuromodulation and Transcranial Magnetic Stimulation (TMS). Whilst techniques as such help to better understand, treat or diagnose neurodegenerative diseases, there is nevertheless a need to assess the potential of these approaches to deliver new and better treatment options for these debilitating diseases.
In this context, JPND is inviting multinational research teams to submit proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects aimed at the development of novel and the advanced use of existing cutting-edge imaging and brain stimulation technologies related to neurodegenerative diseases.
Professor Philippe Amouyel, University of Lille (France) and Chair of the JPND Management Board says: "The incredible progresses of brain imaging and brain stimulation during the last ten years, thanks to the development of new technologies, bioinformatics and artificial intelligence, offer new opportunities to better diagnose and alleviate the consequences of neurodegenerative diseases. For its 2020 transnational call, JPND has decided to support ambitious and innovative research projects that will take stock of these new approaches in a trans-disciplinary context. We hope that this highly competitive call will allow us to assess the potential of these approaches to deliver new and better treatment options.”
Proposals submitted under this call must focus on one or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, Prion diseases, Motor neuron diseases, Spinocerebellar ataxia (SCA), Huntington’s disease, Spinal muscular atrophy (SMA).
In addition, proposals must focus on one or several of the following research areas:
- Imaging technologies
- Development of novel imaging technologies
- Improvements to the application of existing cutting-edge imaging technologies
- Brain stimulation techniques
- New or improved applications of both invasive and non invasive brain stimulation techniques for the diagnosis and treatment of neurodegenerative diseases
Pre-proposals must be submitted no later than 15:00h C.E.T. on March 6, 2020.
For more information about the call, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis2.12.2025 12:32:00 CET | Press release
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose portion in healthy volunteers to rapidly generate foundational safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. These findings will inform dose selection and scheduling for the subsequent multiple ascending dose portion in approximately 40 adults with atopic dermatitis (AD), which will evaluate safety, PK/PD, and early clinical activity versus placebo. Data from both study segments are expected to guide dose selection for a planned Phase 2a trial in AD aimed at establishing clinical pro
AI Takes Center Stage as the Major Threat to Cybersecurity in 20262.12.2025 12:00:00 CET | Press release
Experian releases its 13th Annual Data Breach Industry Forecast highlighting six predictions for 2026 that include several ways AI may have an impact Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/ Experian's 2026 Data Breach Industry Forecast Now in its 13th year, the forecast offers six insights into how cybercriminals are leveraging emerging technologies to create more convincing identities, evade detection, and exploit new digital frontiers. From synthetic profiles and autonomous AI agents to shape-shifting malware and even brain-computer interface vulnerabilities, the 2026 predictions p
Buro Happold Signs Landmark Agreement with Expo 2030 Riyadh Company to Deliver Detailed Master Plan and Infrastructure and Public Realm Design for Expo 2030 Riyadh2.12.2025 11:00:00 CET | Press release
Buro Happold, a leading global engineering, design and advisory consultancy, has signed a major contract with Expo 2030 Riyadh Company to serve as the lead design consultant for the detailed master plan and detailed design of public realm, landscape, infrastructure and utilities for Expo 2030 Riyadh and its legacy. This partnership represents a significant step toward delivering an event billed as “An Unprecedented World Expo”. Expo 2030 Riyadh is expected to feature nearly 197 participating countries and attract over 42 million visits to Pavilions covering approximately 6 million sqm. The event will offer a unique opportunity for participants to address shared challenges and showcase pioneering solutions for a sustainable future. Under the agreement, Buro Happold will provide comprehensive design and technical services, including, development of the detailed master plan, including a focus on event requirements and legacy phase elements, detailed design of the infrastructure works, uti
ThetaRay Report Warns Europe’s AML System at ‘Breaking Point’ as New Regulations Make AI Adoption Inevitable2.12.2025 11:00:00 CET | Press release
Study by EU regulatory expert Prof. Andrea Minto and ThetaRay VP Regulatory Affairs Yaron Hazan finds legacy AML tools unfit for Europe’s new regulatory era ThetaRay, a global leader in Cognitive AI financial crime compliance, today released a landmark study on the future of anti-money laundering in Europe. The study warns that Europe’s anti-money laundering (AML) system is approaching structural failure, and that financial institutions will be unable to meet upcoming supervisory expectations without advanced AI-driven monitoring and customer screening systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202058684/en/ Next Generation AML Solutions The report, “Next-Generation AML Solutions: An Analysis of AI-Based Tools vis-à-vis the Reform of the European AML Institutional and Substantive Architecture,” offers some of the most comprehensive examinations to date of how the EU’s sweeping AML reform package and the Artif
Siren Secures Investment to Advance AI-Driven Investigations for National Security2.12.2025 10:30:00 CET | Press release
Decade-Long Partnership Expands Unified Platform For Agencies To Combat Complex Threats Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The investment deepens a decade-long partnership between the two companies and accelerates development of Siren’s AI-driven platform, including Siren’s newly launched K9 AI Companion, used by national security, law enforcement, and financial crime agencies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202354147/en/ Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The partnership combines the Elasticsearch Platform, which delivers real-time search, retrieval and anomaly detection across structured, unstructured, and streaming data, with Siren’s patented investigative intelligence technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom